Last reviewed · How we verify
NCT05453318
Efficacy and Acceptability of Thermal Ablation in the Treatment of Cervical Neoplasia
NA trial testing Treatment of cervical neoplasia by thermal ablation in Cervical Neoplasm in 119 participants. Completed in 17 August 2020.
17 August 2020
Quick facts
| Lead sponsor | International Agency for Research on Cancer |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 119 |
| Start date | 17 October 2017 |
| Primary completion | 17 August 2020 |
| Estimated completion | 17 August 2020 |
| Sites | 1 location across Morocco |
Drugs / interventions tested
- Treatment of cervical neoplasia by thermal ablation
Conditions studied
- Cervical Neoplasm — all drugs for Cervical Neoplasm →
Sponsor
International Agency for Research on Cancer
Who can join
Adults 25 to 50, female only, with Cervical Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Longitudinal study in two referral centers in Morocco to evaluate the effectiveness, the acceptability and safety of thermal ablation in the treatment of cervical neoplasia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05453318
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Treatment of cervical neoplasia by thermal ablation
Trials testing the same drug.
- NCT05211271 — Evaluating Thermal Ablation in the Treatment of Cervical Neoplasia · NA · completed
Other recruiting trials for Cervical Neoplasm
Currently open trials in the same condition.
- NCT05994300 — Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer · NA · active not recruiting
Other International Agency for Research on Cancer trials
Trials by the same sponsor.
- NCT07256912 — A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared t · Phase 4 · not yet recruiting
- NCT07193030 — Peer-Led Intervention To Reduce Alcohol Binge Drinking Among University Students In Romania · NA · not yet recruiting
- NCT05286034 — Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme · NA · recruiting
- NCT06749847 — HPV Self-sampling in the General Population · NA · recruiting
- NCT07407153 — Triaging of Women Detected With a Breast Lump on Clinical Breast Examination Using Portable Ultrasound Device · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05453318 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Agency for Research on Cancer
- Last refreshed: 12 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05453318.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing